Published in Drug Law Weekly, March 16th, 2004
Modrenal is approved in the United Kingdom for the treatment of advanced post-menopausal breast cancer and was commercially launched in May 2003.
The phase II open label clinical trial in prostate cancer is expected to enroll 43 patients, staged in two groups. Once a single positive response is seen in the first group of 18 patients, a further 25 will be enrolled. Enrollment is expected to take place over the next 12 months. The primary endpoint of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.